Extensive-disease small-cell lung cancer
Conditions
Interventions
The test group:Traditional Chinese medicine granules combined with chemotherapy
The control group:Placebo granules combined with chemotherapy
Sponsors
Beijing Hospital of TCM, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) patients diagnosed with small cell lung cancer by cytology or histology with distant organ metastasis and/or lymph node metastasis of the contralateral hilar lung in extensive-stage (via cranial MRI, chest CT, bone scan, abdominal CT or PET/CT); (2) did not receive radiotherapy, chemotherapy or surgical treatment, with evaluable lesions; (3) ECOG score 2, and the expected survival time is > for 3 months; (4) aged 18-75 years, with serious diseases of heart, brain, kidney, liver, blood and other systems; (5) agree to participate in this study and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) massive pleural or peritoneal effusion or pericardial effusion causes dyspnea; (2) symptomatic bone metastases requiring radiotherapy; (3) brain metastasis; (4) pregnant or lactating women, or serious diseases of heart, lung, liver, kidney, blood and other systems; (5) patients who are known to be allergic to the study drugs; (6) patients undergoing other drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;Safety index; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;PFS;QOL;TCM syndromes related to lung cancer;tumor markers; | — |
Countries
China
Contacts
Public ContactGuowang Yang
Beijing Hospital of TCM, Capital Medical University
Outcome results
None listed